Paul M Barr, Chungwen Wei, James Roger, Julia Schaefer-Cutillo, Jennifer L Kelly, Alexander F Rosenberg, John Jung, Iñaki Sanz, Jonathan W Friedberg
Cell signaling initiated by the B cell receptor is critical to normal development of B lymphocytes, most notably at the transitional B cell stage. Inhibition of this signaling pathway with the syk inhibitor, fostamatinib, has produced significant efficacy in lymphoid malignancies and autoimmune conditions. Here, we demonstrate that short-term use of fostamatinib impairs B lymphocyte development at the transitional stage without affecting mature B cell populations. Additionally, IL-10 producing B cells remained relatively constant throughout the treatment period...
March 2012: Clinical Immunology: the Official Journal of the Clinical Immunology Society